Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (258)	1/17/1998 9:19:00 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 328

James, The word/rumor is that Nexstar is having problems selling their Ambisone drug due to the high cost. It appears that they are trying to sell it for about $900 for a treatment when two other companies have competing drugs that sell for about $240 and $400 each. Supposedly, the University of Wisconsin Hospital and maybe others have stop using the drug because of this issue. I agree that NXTR could be a short squeeze candidate but it would take some excellent news to do so.

To: james who wrote (258)	1/18/1998 12:25:00 AM
From: james	Read Replies (1) \| Respond to of 328

The most interesting aspect of nxtr's selex tech is quoted from the pnas paper: << It is not uncommon for a winning ligand from SELEX to have a nanomolar Kd when the target is a professional nucleic acid binding protein, while we have seen many picomolar Kd values for other protein targets. >> PICOMOLAR compounds are rare, sort of compounds of a life time for researchers in drug discovery business. selex achieves this easily in that its starting libraries are HUGE & RANDOM. Most pharms compound libraries are only a tiny fraction of selex, & they are not random. So the chance of finding a winning drug candidate by selex in short period of time is much higher. Just interesting, interesting...................